Advertisement

Topics

Venn Life Sciences eyes first acquisition target after £4.5mln raise

07:35 EDT 14 Jun 2019 | Proactive Investors

Cathal Friel, chief executive of Venn Life Sciences Holdings plc (LON:VENN) and founder of Open Orphan, speaks to Proactive London's Andrew Scott after successfully raising £4.5mln in a share placing.

Friel is reversing Open Orphan into Venn in a £5.7mln all-paper deal to bring to the market his platform that helps pharma companies commercialise their products in Europe.

Friel and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.

Original Article: Venn Life Sciences eyes first acquisition target after £4.5mln raise

NEXT ARTICLE

More From BioPortfolio on "Venn Life Sciences eyes first acquisition target after £4.5mln raise"

Advertisement
Quick Search
Advertisement
Advertisement